icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Janssen at AASLD
 
 
  Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline
http://www.natap.org/2013/HCV/101013_01.htm
 
AASLD: Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-na´ve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials - (11/10/13)
 
AASLD: Simeprevir (TMC435) with pegylated interferon-a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE Phase III trial - (11/10/13)
 
AASLD: Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies - (11/10/13)
 
AASLD: SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-na´ve and prior null responder patients: The COSMOS study - (11/05/13)
 
AASLD: Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Na´ve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients - (11/02/13) press release
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013